Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab in biologic-naïve Korean patients with early uncomplicated Crohn's disease
KCT0008502Phase 4Terminated
- Sponsor
- Takeda
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started May 2024; status: terminated.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on KCT0008502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0008502.